These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 19138940

  • 1. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG, Moe JL.
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG, DiMasi JA, Long G.
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [Abstract] [Full Text] [Related]

  • 4. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B.
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 7. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ, Graham SJ.
    Science; 2009 Oct 16; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS, Solomon DH.
    N Engl J Med; 2010 Jun 03; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incentives for orphan drug research and development in the United States.
    Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J.
    Orphanet J Rare Dis; 2008 Dec 16; 3():33. PubMed ID: 19087348
    [Abstract] [Full Text] [Related]

  • 13. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM.
    Bull World Health Organ; 2004 Oct 16; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
    Wolff ME.
    J Pharm Sci; 2011 Aug 16; 100(8):3044-3054. PubMed ID: 21472728
    [Abstract] [Full Text] [Related]

  • 17. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
    Refoios Camejo R, McGrath C, Herings R.
    Health Policy; 2011 Apr 16; 100(1):18-24. PubMed ID: 20864202
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
    Arno PS, Bonuck K, Davis M.
    Milbank Q; 1995 Apr 16; 73(2):231-52. PubMed ID: 7776947
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.